Of interest, the protective effects of aspirin in LS patients has specifically been shown to extend to a subgroup of individuals with obesity as a risk factor for the development of CRC; in LS patients with MLH1 mutation, obesity-related excess CRC risk was abrogated by aspirin use [89]. The gene discussed is MLH1; the disease is colorectal carcinoma.